Informations:
Erreur:
ID
13162
Description
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I); ODM derived from: https://clinicaltrials.gov/show/NCT00317642
Lien
https://clinicaltrials.gov/show/NCT00317642
Mots-clés
Versions (1)
- 20/01/2016 20/01/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
20 janvier 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Acute Myelogenous Leukemia NCT00317642
Eligibility Acute Myelogenous Leukemia NCT00317642
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myelogenous Leukemia NCT00317642
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
AML
Item
have a diagnosis of acute myelogenous leukemia (aml) according to world health organization (who) classification
boolean
C0023467 (UMLS CUI [1])
relapsed or refractory
Item
relapsed after receiving up to 2 prior induction regimens (i.e. first or second relapse)or are refractory to not more than one prior combination chemotherapy induction regimen
boolean
C0392920 (UMLS CUI [1])
age
Item
be ≥ 55 years of age
boolean
C0001779 (UMLS CUI [1])
ecog score
Item
have an eastern cooperative oncology group (ecog) score of 0-2
boolean
C1520224 (UMLS CUI [1])
compliance
Item
be able to comply with study procedures and follow-up examinations
boolean
C1321605 (UMLS CUI [1])
fertility and contraception
Item
be nonfertile or agree to use birth control during the study through the end of treatment visit and for at least 90 days after the last dose of study drug
boolean
C0015895 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
liver and renal function
Item
have adequate liver and renal function as indicated by certain laboratory values
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232804 (UMLS CUI [2])
clofarabine
Item
received previous treatment with clofarabine
boolean
C0092777 (UMLS CUI [1])
cytarabine
Item
received bolus, intermediate or high-dose cytarabine as induction therapy unless certain remission criteria are met
boolean
C0010711 (UMLS CUI [1])
hematopoietic stem cell transplant
Item
have received a hematopoietic stem cell transplant (hsct) within the previous 3 months
boolean
C0472699 (UMLS CUI [1])
graft versus host disease
Item
have moderate or severe graft versus host disease (gvhd), whether acute or chronic
boolean
C0018133 (UMLS CUI [1])
chemotherapy or investigational therapy
Item
are receiving any other chemotherapy or investigational therapy. patients must have been off prior aml therapy for at least 2-6 weeks prior to entering study.
boolean
C0392920 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013230 (UMLS CUI [2])
psychiatric disorder that would interfere with consent, study participation, or follow-up
Item
have a psychiatric disorder that would interfere with consent, study participation, or follow-up
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
infection
Item
have an active, uncontrolled infection
boolean
C0009450 (UMLS CUI [1])
severe concurrent disease, or have a history of serious organ dysfunction
Item
have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system
boolean
C0009488 (UMLS CUI [1])
malignancy
Item
have been diagnosed with another malignancy, unless disease-free for at least 5 years; patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed; patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed.
boolean
C0006826 (UMLS CUI [1])
cns leukemia
Item
have clinical evidence suggestive of central nervous system (cns) involvement with leukemia unless lumbar puncture confirms absence of leukemic blasts in the cerebrospinal fluid(csf)
boolean
C1332884 (UMLS CUI [1])
HIV
Item
known hiv positivity
boolean
C0019682 (UMLS CUI [1])
pregnancy or lactation
Item
are pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])